Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy

Annals of Oncology

Volumn 21, Issue 5, 2010, Pages 1083-1088

  Aapro, M ^a   Fabi, A ^b   Nole F ^c   Medici, M ^c   Steger, G ^d   Bachmann, C ^e   Roncoroni, S ^f   Roila, F ^g  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f HELSINN HEALTHCARE SA   (Switzerland)

^g S MARIA HOSPITAL   (Italy)

Author keywords

5 HT3 receptor antagonist; CINV; Dexamethasone; Nausea; Palonosetron; Vomiting

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; PALONOSETRON; PLACEBO;

ADULT; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; NAUSEA AND VOMITING; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 77953349334     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp584     Document Type: Article

References (15)

1. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007; 61: 162-175.
2. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358: 2482-2494.
3. Aapro MS, Macciocchi A, Gridelli C. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting in elderly patients. J Support Oncol 2005; 3: 369-374.
4. Kris GM, Hesketh JP, Somerfield RM et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932-2947.
5. MASCC Antiemetic Guidelines. http://www.mascc.org/media/Resource_centers/MASCC_Guidelines_Update.pdf (12 September 2009, date last accessed).
6. NCCN. Clinical Practice Guidelines. Antiemesis. V.3. 2009. www.nccn.org/(12 September 2009, date last accessed).
7. Jordan K, Kasper C, Schmoll HJ. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment. Eur J Cancer 2005; 41: 199-205.
8. Decker GM, DeMeyer ES, Kisko DL. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol 2006; 4: 35-41.
9. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol 2007; 18: 233-240.
10. Roila F, Hesketh PJ, Herrstedt J. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy-and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-28.
11. Vardy J, Chiew KS, Galica J et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 2006; 94: 1011-1015.
12. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-109.
13. Grunberg SM, Osoba D, Hesketh PJ et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update. Support Care Cancer 2005; 13: 80-84.
14. Aapro MS, Plezia PM, Alberts DS et al. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol 1984; 2: 466-471.
15. Grunberg SM, Dugan M, Muss H et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 2009; 17: 589-594.